 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Efzofitimod demonstrated immune regulatory function improving disease outcomes and mitigating fibrosis in animal models.SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq...

aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023

Piper Sandler analyst Yasmeen Rahimi initiated coverage with a Buy rating on aTyr Pharma (LIFE Research Report) today and set a price target of...

aTyr Pharma (LIFE) Receives a Buy from Piper Sandler

Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis expected to complete enrollment early in the second quarter of 2024. Phase 2 EFZO-CONNECT study of efzofitimod in SSc-ILD initiated...

aTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate Update

SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its...

aTyr Pharma to Present at November Investor Conferences

Multiple centers in the U.S. are open for enrollmentSAN DIEGO, Oct. 31, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the Company), a clinical stage biotechnology company...

aTyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT  Study of Efzofitimod in Patients with SSc-ILD

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

aTyr Pharma presents efzofitimod data

Post-hoc analysis from Phase 1b/2a study in pulmonary sarcoidosis presented at the European Respiratory Society (ERS) International Congress 2023. 7.7% of patients in the 3.0 and 5.0 mg/kg...

aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes

SAN DIEGO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Jill Broadfoot, Chief Financial Officer, will present a ...

aTyr Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference

JonesTrading analyst Sean Kim PhD reiterated a Buy rating on aTyr Pharma (LIFE Research Report) today and set a price target of $12.00. The compa... JonesTrading analyst Sean Kim PhD reiterated a Buy rating on aTyr Pharma (LIFE  Research Report...

JonesTrading Sticks to Its Buy Rating for aTyr Pharma (LIFE)

Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis currently enrolling in the U.S., Europe and Japan. Phase 2 EFZO-CONNECT study of efzofitimod in SSc-ILD expected to initiate in the third quarter of 2023. Ended the second quarter of 2023 with $112.0 million in cash, cash equivalents and...

aTyr Pharma Announces Second Quarter 2023 Results and Provides Corporate Update

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Watchers	10,852
52-Wk Low	$1.08
52-Wk High	$2.70

Market Cap	$74.37M
Volume (M)	149,111.00
52-Wk High	$2.70
52-Wk Low	$1.08

LIFE Atyr Pharma Inc

About

Feed

News

Sentiment

Earnings

Fundamentals